David Gooray, MD
Cardiovascular Disease · Largo, MDNPI 1720070261
Payments from drug & device makers
Across 754 payments — averaging $441.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$124K
- Lilly USA, LLC$115K
- Novartis$69K
- Bayer$10K
- Alnylam Pharmaceuticals Inc.$5K
- Abbott$2K
- plus $9K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 153 | $123,527 |
| Lilly USA, LLC | 142 | $115,025 |
| Novartis | 115 | $68,593 |
| Bayer | 34 | $10,056 |
| Alnylam Pharmaceuticals Inc. | 21 | $4,677 |
| Abbott | 17 | $1,730 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $1,514 |
| Atricure, Inc. | 10 | $1,483 |
| E.r. Squibb & Sons, L.L.C. | 41 | $848 |
| AstraZeneca | 32 | $802 |
| Merck | 34 | $775 |
| Novo Nordisk | 20 | $679 |
| Actelion Pharmaceuticals US, Inc. | 12 | $448 |
| Boston Scientific | 9 | $441 |
| Gilead | 37 | $402 |
| Corcept Therapeutics | 4 | $197 |
| Scpharmaceuticals Inc. | 7 | $170 |
| GSK | 7 | $153 |
| Lexicon Pharmaceuticals, Inc. | 7 | $141 |
| Azurity Pharmaceuticals, Inc. | 11 | $136 |
| Pfizer | 7 | $135 |
| Portola Pharmaceuticals, LLC | 1 | $126 |
| Bridgebio Pharma, Inc. | 1 | $109 |
| Amarin Pharma, Inc. | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $54 |
| Ironwood Pharmaceuticals, Inc | 3 | $51 |
| AbbVie | 3 | $50 |
| Johnson & Johnson(2 entities) | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $36 |
| Intercept Pharmaceuticals, Inc. | 1 | $25 |
| Mannkind Corporation | 1 | $22 |
| Heartflow, Inc. | 1 | $20 |
How this compares
$332,653 in reported general payments places this provider in the 90th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Largo
- Leighton ForresterLargo$29K
- Christopher DefilippiBaltimore$9.2M
- Thorsten LeuckerBaltimore$7.1M
- Joao LimaBaltimore$5.6M
- Jeffrey ColeBaltimore$4.8M
- Carlos InceBaltimore$3M
- Paul GurbelBaltimore$2.6M
- Navin KapurBaltimore$1.8M
- Vineet VenugopalLanham$1.5M
- Robert WeissBaltimore$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.